|
|
Post by Clement on May 29, 2024 10:01:48 GMT -5
mango:2. MannKind has never said that. Will you please provide the source for your information? This is directly in the mnkd press release: "However, for some drug candidates, such as Clofazimine, that may require a significantly higher drug payload, the iSPERSE formulation technology may be better suited for developing viable powders.”Also, I was sloppy in my wording. I should have said dreamboat instead of cricket. Me, too. That quote from the release makes it sound like clofazimine on Technoshere didn't work out. |
|
|
|
Post by mango on May 29, 2024 10:02:11 GMT -5
mango:2. MannKind has never said that. Will you please provide the source for your information? This is directly in the mnkd press release: "However, for some drug candidates, such as Clofazimine, that may require a significantly higher drug payload, the iSPERSE formulation technology may be better suited for developing viable powders.” Also, I was sloppy in my wording. I should have said dreamboat instead of cricket. No worries. |
|
|
|
Post by mango on May 29, 2024 10:05:07 GMT -5
mango:2. MannKind has never said that. Will you please provide the source for your information? This is directly in the mnkd press release: "However, for some drug candidates, such as Clofazimine, that may require a significantly higher drug payload, the iSPERSE formulation technology may be better suited for developing viable powders.”Also, I was sloppy in my wording. I should have said dreamboat instead of cricket. Me, too. That quote from the release makes it sound like clofazimine on Technoshere didn't work out. I want to say Mike has mentioned a few times in the past that it is/was/has been difficult to formulate clofazimine with FDKP. What MannKind is showing us is they can adjust to the situation and pivoted themselves into a positive deal to still potentially achieve the desired outcome. I think this was an excellent deal. |
|
|
|
Post by Clement on May 29, 2024 10:09:56 GMT -5
It sounds like no real estate changed hands. Mannkind assumes the lease of some furnished buildings.
|
|
|
|
Post by uvula on May 29, 2024 10:13:04 GMT -5
I like mango's take on this. Mnkd ran into an issue and figured out a way to solve it. That is definitely a good thing.
I'll combine my negative spin and mango's positive spin and conclude that this new deal is neutral.
|
|
|
|
Post by cretin11 on May 29, 2024 10:40:11 GMT -5
Market certainly not impressed but what else is new. Agree with uvula's take of neutral on this deal, not a big needle mover either way, at least doesn't appear to be another misstep like VGo.
|
|
|
|
Post by mango on May 29, 2024 10:52:05 GMT -5
A little due diligence on the new dry powder formulation (this is not a deep dig!):
• iSPERSE can deliver small molecules, drug combinations, peptides, proteins, and nucleic acids
• Can delivery large doses; tens of milligrams
• Can be used with almost any device (ie, metered-dose, reservoir, or blister-based inhalers). So it looks like it could pair with MannKind’s Dreamboat
• Requires low inspiratory flow for deep lung deposition. This is good because MannKind’s is a high resistance inhaler which requires low inspiratory effort/flow rate.
• Broad IP portfolio into 2030s
|
|
|
|
Post by otherottawaguy on May 29, 2024 11:09:03 GMT -5
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Co
PR Newswire
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
PR Newswire
Wed, May 29, 2024, 8:45 AM EDT5 min read
In this article:
MNKD
-1.94%
PULM
-0.55%
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device.
Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.
Master service agreement in place for MannKind to provide future iSPERSE™ dry powder drug formulation development services to Pulmatrix.
BEDFORD, Mass., May 29, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).
(PRNewsfoto/Pulmatrix, Inc.)
(PRNewsfoto/Pulmatrix, Inc.)
Ted Raad, Chief Executive Officer of Pulmatrix, commented, "MannKind's interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind's Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine."
The Company entered into a cross license with MannKind pursuant to which MannKind will grant Pulmatrix a perpetual, royalty free, exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of PUR3100, our proprietary formulation of dihydroergotamine (DHE) with iSPERSE™, and a perpetual, royalty free, non-exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of any dry powder formulation formulated for the treatment or prevention of neurological disease. As part of the cross-license, the Company will grant MannKind a perpetual, royalty free, exclusive license to formulate iSPERSE™ with clofazimine for inhalation by humans for the treatment or prevention of infection, for the treatment or prevention of nontuberculous mycobacteria lung disease in humans, and with insulin for inhalation by humans for the treatment or prevention of diabetes. We will also grant MannKind a perpetual, royalty free, non-exclusive license to formulate iSPERSE™ for inhalation for the treatment or prevention of endocrine disease and for inhalation for the treatment or prevention of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans ("ILD").
As part of the transaction, MannKind will assume the lease of our Bedford, Mass., R&D facility along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory. To maintain continuity of iSPERSE™ platform knowledge, MannKind plans to hire some members of the Pulmatrix R&D staff.
The agreements are anticipated to close in July 2024.
About Pulmatrix, Inc.
Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat central nervous system ("CNS"), respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes
|
|
|
|
Post by sayhey24 on May 29, 2024 11:09:32 GMT -5
What are we doing here?
We are out-licensing MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine (DHE) for migraine treatment. The cricket is for Technosphere. Is Pulmatriz planning on putting DHE on Technosphere?
What molecule was it Al Mann was using for migraines?
|
|
|
|
Post by otherottawaguy on May 29, 2024 11:09:54 GMT -5
Didn't see this here but saw it over on IV.
OOG
|
|
|
|
Post by Clement on May 29, 2024 11:54:05 GMT -5
If I like this deal, does that mean I am a traitor to Al Mann?
|
|
|
|
Post by ktim on May 29, 2024 11:57:34 GMT -5
I like mango's take on this. Mnkd ran into an issue and figured out a way to solve it. That is definitely a good thing. I'll combine my negative spin and mango's positive spin and conclude that this new deal is neutral. What was the issue? Unless Clofazimine requires use throughout the day, I don't see that it would be worth the expense of trials to move away from the initial (anticipated) approval of the nebulized version. Obviously they want the option, but why really do it. My stance is similar to yours, though not exactly. I have no idea whether the actual deal would be positive, negative or neutral, but my opinion on it is neutral since I don't pretend to know enough about the deal and the new technology to make a judgement. That's a little different route to being neutral than taking the predictable dour and Pollyannaish views here and averaging them, lol Using the latter method would always yield MNKD actions as neutral. |
|
|
|
Post by hellodolly on May 29, 2024 12:16:24 GMT -5
A carton or two of plastic whistle looking devices into perpetuity for another DPI, FDA approved manufacturing facility? Man did he pull one over on these guys.
very simplistic version of comedy.
|
|
|
|
Post by sayhey24 on May 29, 2024 12:39:48 GMT -5
If I like this deal, does that mean I am a traitor to Al Mann? Al didn't invent Technosphere. Sol Steiner did. I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse? I guess we all kind of figured they had issues putting clofazimine on TS so maybe iSpherse helps? Who knows maybe iSpherse would work better with Saxenda but Al Mann had some pretty great results putting native GLP1 on Technosphere. I am not sure I like paying for more R&D when we need to do the afrezza GLP1 trial and we need to do the Saxenda DPI trails. I also thought we had already put something on TS for migraines and had some good initial results but I don't remember what happened here. I just hope we are not signing up for another boondoggle. |
|
|
|
Post by radgray68 on May 29, 2024 12:44:11 GMT -5
At RBC, Mike said that TGFBeta was proving more difficult to formulate than expected. He also stated we were at the point of making a decision (some decisions?) on that particle. This was just a few weeks ago so I have to assume it has to do with that.
Besides, he has stated a few times that our little company is bursting at the seams with our current products and pipelines so this helps us in that way too.
Plus, if they can move the migraine med along a little, maybe we buy them out completely later. Let them take the risk for now. Just my thoughts
|
|
